<DOC>
	<DOC>NCT00543556</DOC>
	<brief_summary>This is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767. This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.</brief_summary>
	<brief_title>MK0767 in Type 2 Diabetes (0767-012)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 Diabetes Mellitus patients between the ages of 21 and 75 inclusive Patient is willing to discontinue current therapy for the duration of the study Patient is not a heavy drinker Patient has a history of Type 1 diabetes and/or ketoacidosis Patient has severe diabetic retinopathy, or nephropathy, or neuropath Patient has has antihyperglycemic therapy including insulin, or rosiglitazone and pioglitazone or 2 or more oral agents in combination within 8 weeks prior to visit 1 Patient has a history of, allergy to, intolerance or hypersensitive to troglitazone, rosiglitazone, or pioglitazone including history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>